Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

About XTL Biopharmaceuticals Stock (NASDAQ:XTLB)

Key Stats

Today's Range
$1.46
$1.55
50-Day Range
$3.43
$5.20
52-Week Range
$1.73
$6.69
Volume
15,652 shs
Average Volume
11,894 shs
Market Capitalization
$8.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Receive XTLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XTLB Stock News Headlines

XTL Biopharmaceuticals Ltd (XTLB)
I want to send you my Cash Calendar
This Calendar reveals the EXACT dates that — if everything goes right — anyone can target cash payouts of $125, $415, and even $1,665. (With just a $1,000 starting stake!) Granted, there were smaller wins and those that did not work out and we cannot promise future returns or against losses, but these payouts don’t require any special knowledge or skills. Anyone can set them up with just three clicks in their brokerage account. And the money can be deposited in their account the very next morning after opening the trade. Again, I want to send this Cash Calendar to you completely FREE. All you have to do is join me for my free Cash Calendar training right here. You don’t want to miss this. There is a very special bonus surprise for everyone who attends.
XTL Biopharmaceuticals Ltd XTLB
XTL Biopharmaceuticals acquires AI firm Social Proxy
XTL Biopharmaceuticals Ltd. (XTLB.TA)
See More Headlines

XTLB Stock Analysis - Frequently Asked Questions

XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP).

Company Calendar

Today
12/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XTLB
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.41 per share

Miscellaneous

Free Float
3,869,000
Market Cap
$8.53 million
Optionable
Not Optionable
Beta
1.16
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:XTLB) was last updated on 12/19/2024 by MarketBeat.com Staff
From Our Partners